Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Research & Development: 2015-2024

Historic Research & Development for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $199.2 million.

  • Editas Medicine's Research & Development fell 58.49% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year decrease of 49.52%. This contributed to the annual value of $199.2 million for FY2024, which is 12.16% up from last year.
  • As of FY2024, Editas Medicine's Research & Development stood at $199.2 million, which was up 12.16% from $177.7 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Research & Development registered a high of $199.2 million during FY2024, and its lowest value of $142.5 million during FY2021.
  • For the 3-year period, Editas Medicine's Research & Development averaged around $184.0 million, with its median value being $177.7 million (2023).
  • In the last 5 years, Editas Medicine's Research & Development soared by 63.05% in 2020 and then declined by 9.80% in 2021.
  • Yearly analysis of 5 years shows Editas Medicine's Research & Development stood at $158.0 million in 2020, then decreased by 9.80% to $142.5 million in 2021, then climbed by 22.77% to $175.0 million in 2022, then grew by 1.54% to $177.7 million in 2023, then grew by 12.16% to $199.2 million in 2024.